









Markets
/
Stocks
/
nasdaq-plur
/

Pluri Inc

PLUR

3.470USD

-0.180-4.93%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

28.32MMarket Cap

LossP/E TTM



Pluri Inc

3.470

-0.180-4.93%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pluri Inc

Currency: USD Updated: 2026-02-06

Key Insights

Pluri Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 155 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pluri Inc's Score

Industry at a Glance

Industry Ranking

155 / 392

Overall Ranking

302 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Pluri Inc Highlights

StrengthsRisks

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.34M.

Fairly Valued

The company’s latest PE is -1.11, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.37M shares, decreasing 2.95% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 33.92K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

12.000

Target Price

+228.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Pluri Inc is 5.51, ranking 354 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 316.00K, representing a year-over-year decrease of 3.07%, while its net profit experienced a year-over-year decrease of 0.54%.

Score

Industry at a Glance

Previous score

5.51

Change



Financials

4.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.09

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Pluri Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Pluri Inc is 7.24, ranking 145 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.11, which is -44.92% below the recent high of -0.61 and -68.29% above the recent low of -1.86.

Score

Industry at a Glance

Previous score

7.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 155/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Pluri Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

12.000

Target Price

+228.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Pluri Inc

PLUR

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Pluri Inc is 6.59, ranking 217 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.91 and the support level at 3.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.01

Change

-0.42

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.073

Buy

RSI(14)

54.681

Neutral

STOCH(KDJ)(9,3,3)

43.375

Sell

ATR(14)

0.206

High Vlolatility

CCI(14)

123.248

Buy

Williams %R

47.191

Neutral

TRIX(12,20)

0.404

Sell

StochRSI(14)

37.965

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.444

Buy

MA10

3.408

Buy

MA20

3.277

Buy

MA50

3.247

Buy

MA100

3.698

Sell

MA200

4.333

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Pluri Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 14.78%, representing a quarter-over-quarter decrease of 24.62%. The largest institutional shareholder is James Simons, holding a total of 33.92K shares, representing 0.37% of shares outstanding, with 6.69% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Chutzpah Holdings Ltd

1.93M

+107.62%

Merchant Adventure Investment Advisors, LLC

1.32M

+3.89%

Plantae Bioscience Ltd

452.70K

Shayna LP

406.98K

-2.93%

Yanay (Yaky)

334.83K

+2.01%

Gunn (John A)

307.25K

Aberman (Zalman)

143.20K

+0.24%

Franco-Yehuda (Chen)

40.06K

Renaissance Technologies LLC

Star Investors

33.92K

+23.72%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pluri Inc is 2.15, ranking 250 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.